ClinicalTrials.gg
CompletedNCT00410410Updated Mar 24, 2015Results posted

A Study of Abatacept in Patients With Active Ulcerative Colitis

A Phase 3 interventional study of abatacept (ABA) and placebo in Ulcerative Colitis, sponsored by Bristol-Myers Squibb. Completed at 144 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-24.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
591
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb — 4 open to participants now, 5 under way, 1 of them phase 3. Colitis, Ulcerative · Bristol-Myers Squibb.

Enrollment
3rd of 17
591 · median 131
Started
2006
with 1 other
Phase 3
5 of 22
none open now
Registered
2nd of 22
by date

Among the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2006, is one of 5 in phase 3, and was the 2nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied

Read the detailed description

The Induction Period First Cohort (IP1C) arms (30/10 mg/kg and 10 mg/kg) were placebo-controlled arms that were used for the primary endpoint and its analysis. The Induction Period Second Cohort arms (IP2C 30/10 mg/kg and 10 mg/kg) were not placebo-controlled, their sole purpose being to provide sufficient numbers of participants for the maintenance phase. The first cohort (IP1C) was randomized to receive placebo or 1 of 3 doses of abatacept. Following completion of the IP1C randomization, a second cohort (IP2C) was randomized to receive 1 of 2 doses of abatacept. After all participants in the IP1C completed or discontinued, the data was locked and the formal analysis for the Induction Period primary endpoint was performed. Summary tables for the second cohort (IP2C) and the Maintenance and Open-label phases were generated from a second, subsequent data lock.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Men or women 18 years or older
  • Ulcerative colitis for at lease 3 months
  • Moderate to severe active ulcerative colitis
  • Inadequate response or intolerance to standard ulcerative colitis treatment
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
591 participants (actual)

Study arms

  • Experimental
    Abatacept (ABA)

    Induction Period; 3 arms for Cohort 1: ABA 30/\~10 mg/kg (ABA administered at 30 mg/kg followed by ABA at \~10 mg/kg), ABA \~10 mg/kg, ABA 3 mg/kg Induction Period; 2 arms for Cohort 2: ABA 30/\~10 mg/kg and Second Cohort ABA \~10 mg/kg 1 arm for maintenance period (ABA \~10 mg/kg)

    Drug: abatacept (ABA)

  • Placebo comparator
    Placebo

    1 arm for induction period 1 arm for maintenance period

    Drug: placebo

  • Other
    abatacept

    1 arm for open-label extension phase (ABA \~10 mg/kg)

    Drug: abatacept

Interventions

  • Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57 (ABA 30/\~10 mg/kg Group). Induction Period 3 months Maintenance Period 12 months

    Also known as: Orencia, BMS-188667

  • Drugplacebo

    Normal saline, IV, 0 mg/kg, every 28 days. Induction Period 3 months Maintenance Period 12 months

  • \~10 mg/kg, once monthly Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued

    Also known as: Orencia, BMS-188667

06

What researchers measure

Primary outcomes

  1. Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.

    Time frame: Week 12 (Day IP-85)

  2. Maintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 12

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.

    Time frame: Month 12 (Day MP-365)

  3. Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: Day OL-1 through the end of the OL

  4. OL; Number of Participants With AEs of Special Interest

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

    Time frame: Day OL-1 through Day OL-729

  5. OL; Number of Participants With Physical Examination Findings

    Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).

    Time frame: Day OL-1 through Day OL-729

  6. OL; Number of Participants With Marked Hematology Laboratory Abnormalities

    High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL.

    Time frame: Day OL-1 through Day OL-729

  7. OL; Number of Participants With Liver and Kidney Function and Electrolyte Laboratory Abnormalities

    Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): \>2 x ULN; aspartate aminotransferase (AST): \>3 x ULN; alanine aminotransferase (ALT): \>3 x ULN; G-Glutamyl transferase (GGT): \>2 x ULN; Bilirubin: \>2 x ULN; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; calcium (Ca): \<0.8 x LLN/\>1.2 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN

    Time frame: Day OL-1 through Day OL-729

  8. OL; Number of Participants With Chemistry and Urinalysis Laboratory Abnormalities

    Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; fasting serum Glu: \<0.8 x LLN/ \>1.5 x ULN; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3

    Time frame: Day OL-1 through Day OL-729

Secondary outcomes

  1. IP; Baseline Mayo Score: IP1C

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.

    Time frame: Baseline

  2. IP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

    Time frame: Week 12 (Day IP-85)

  3. IP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point

    Time frame: Week 12 (Day IP-85)

  4. IP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.

    Time frame: Week 12 (Day IP-85)

  5. IP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C

    The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.

    Time frame: Baseline

  6. IP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C

    The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.

    Time frame: Baseline (Day IP-1), Day IP-85 (Week 12)

  7. IP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.

    Time frame: Day IP-85 (Week 12)

  8. IP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.

    Time frame: Day IP-85 (Week 12)

  9. IP; Number of Participants With Mayo Physician Global Assessment (PGA) Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.

    Time frame: Day IP-85 (Week 12)

  10. IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C

    The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

    Time frame: Week 12 (Day IP-85)

  11. IP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C

    The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

    Time frame: Week 12 (Day IP-85)

  12. IP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C

    The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

    Time frame: Week 12 (Day IP-85)

  13. IP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

    Time frame: Week 12 (Day IP-85)

  14. IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation: IP1C + IP2C

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: Day IP-1 through Day IP-85

  15. IP; Number of Participants With AEs Of Special Interest: IP1C + IP2C

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

    Time frame: Day IP-1 through Day IP-85

  16. IP; Number of Participants With Physical Examination Findings: IP1C + IP2C

    Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).

    Time frame: Day IP-1 through Day IP-85

  17. IP; Number of Participants With Marked Hematology Laboratory Abnormalities: IP1C

    High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL.

    Time frame: Day IP-1 through Day IP-85

  18. IP; Number of Participants With Marked Liver and Kidney Function and Electrolyte Laboratory Abnormalities: IP1C

    Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): \>2 x ULN; aspartate aminotransferase (AST): \>3 x ULN; alanine aminotransferase (ALT): \>3 x ULN; G-Glutamyl transferase (GGT): \>2 x ULN; Bilirubin: \>2 x ULN; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; Sodium (Na): \<0.95 x LLN/ \>1.05 x ULN; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; calcium (Ca): \<0.8 x LLN/\>1.2 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN

    Time frame: Day IP-1 through Day IP-85

  19. IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP1C

    Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3

    Time frame: Day IP-1 through Day IP-85

  20. IP; Number of Participants With Marked Hematology, Liver and Kidney Function, and Electrolyte Laboratory Abnormalities: IP2C

    High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; Sodium (Na): \<0.95 x LLN/ \>1.05 x ULN; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN;

    Time frame: Day IP-1 through Day IP-85

  21. IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP2C

    Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3

    Time frame: Day IP-1 through Day IP-85

  22. IP; Number of Participants With Abatacept-Induced Antibodies: IP1C + IP2C

    A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

    Time frame: For participants treated in MP: Day IP-1 (Baseline) to Day MP-1 (Day IP-85). For participants treated in OL directly after IP: Day IP-1 to Day OL-1. For participants treated only in IP: All measurements after Day IP-1 (including follow-up visits)

  23. MP; Number of Participants in Clinical Remission at Month 12

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

    Time frame: Month 12 (Day MP-365)

  24. MP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) at Month 12

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point

    Time frame: Month 12 (Day MP-365)

  25. MP; Number of Participants in Clinical Remission at Both Month 6 and Month 12

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

    Time frame: Month 6 (Day MP-169), Month 12 (Day MP-365)

  26. MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids and Achieved Clinical Remission by Month 12

    Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

    Time frame: Day MP-365 (Month 12)

  27. MP; Mean Change From Baseline to Month 12 in IBDQ

    The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.

    Time frame: Day MP-365

  28. MP; Mean Change From Baseline to Month 12 in Short Form-36 (SF-36)

    The SF-36 is a validated instrument to measure health-related quality of life across multiple disease states. Individual subscale scores and 2 summary scores are calculated: (1) physical component summary (PCS) which includes physical functioning, role-physical, bodily pain, and general health; (2) mental component summary (MCS) which includes vitality, social functioning, role-emotional, and mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight, with values ranging from worse health (0) to best health (100).

    Time frame: Day MP-365

  29. MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids for 90 Consecutive Days and Achieved Clinical Remission by Month 12

    Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

    Time frame: Day MP-365 (Month 12)

  30. MP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Month 12

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.

    Time frame: Day MP-365 (Month 12)

  31. MP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Month 12

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.

    Time frame: Day MP-365 (Month 12)

  32. MP; Number of Participants With Mayo PGA Subscores Indicating Mild Disease (≤1 Point) at Month 12

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.

    Time frame: Day MP-365 (Month 12)

  33. MP; Number of Participants With Clinical Response at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)

    The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

    Time frame: Month 12 (Day MP-365)

  34. MP; Number of Participants With Clinical Remission at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)

    The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

    Time frame: Month 12 (Day MP-365)

  35. MP; Number of Participants With Clinical Mucosal Healing at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

    Time frame: Month 12 (Day MP-365)

  36. MP; Number of Participants With Abatacept-Induced Antibodies

    A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

    Time frame: For participants not entering OL: All measurements starting after Day MP-1 (including follow-up visits). For participants entering OL: From first measurement after Day MP-1 to Day MP-365 (Day OL-1).

  37. MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: Day MP-1 through Day MP-365

  38. MP; Number of Participants With AEs of Special Interest

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

    Time frame: Day MP-1 through Day MP-365

  39. MP; Number of Participants With Physical Examination Findings

    Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).

    Time frame: Day IP-85 through Day MP-365

  40. MP; Number of Participants With Marked Hematology Laboratory Abnormalities

    High=greater than ULN, Low=lower than LLN. LLN/ULN= HGB: \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; PLT: \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL; GGT: \>2 x ULN; Bilirubin: \>2 x ULN; BUN: \>2 x BL; Na: \<0.95 x LLN/ \>1.05 x ULN; K: \<0.9 x LLN/ \>1.1 x ULN; Ca: \<0.8 x LLN/\>1.2 x ULN

    Time frame: Day IP-85 through Day MP-365

  41. MP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities

    Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; fasting serum Glu: \<0.8 x LLN/ \>1.5 x ULN; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3

    Time frame: Day IP-85 through Day MP-365

  42. OL; Number of Participants With Clinical Response Over Time

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.

    Time frame: Day OL-1 through Day OL-729

  43. OL; Number of Participants With Clinical Remission Over Time

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

    Time frame: Day OL-1 through Day OL-729

  44. OL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) During OL

    The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point

    Time frame: Open-Label Period (Day OL-1 through Day OL-729)

  45. OL; Number of Participants With Clinical Response or Clinical Remission Upon Retreatment With Abatacept Among Those Who Received Abatacept in the IP or MP Period

    The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Clinical remission = Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Change from Baseline= post-Baseline - Baseline value.

    Time frame: Last Study Visit (Day OL-729)

  46. OL; Number of Participants With Abatacept-Induced Antibodies

    A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

    Time frame: For participants receiving OL medication, all measurements starting after Day OL-1 (including follow-up visits and at 56 and 85 days after last dose)

  47. OL; Number of Participants Using Corticosteroids During OL

    Participants taking oral corticosteroids (equivalent of ≤ 30 mg prednisone daily) must have met minimum treatment duration at entry into IP and had stable dose for ≥2 weeks prior to entry into the IP.

    Time frame: Day OL-1 through Day OL-729

07

Results

Posted Dec 2, 2010
Limitations and caveats
This study was terminated after review of the IP1C results due to lack of efficacy. Enrollment for the MP and for IP2C was not completed. Participants in MP, IP2C, and OL were early terminated at the time of study termination.

Participant flow

In this study, a first cohort (Induction Period First Cohort, IP1C) of 490 participants was randomized and used for analysis of the primary endpoint. Following randomization of IP1C, a second cohort (IP2C) of 146 participants was randomized to provide a sufficient number of participants for the Maintenance Period.

Induction Period (IP)
Participant flow — Induction Period (IP)
MilestoneInduction Period Cohort 1 (IP1C)-Abatacept (ABA) 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-PlaceboIP Cohort 2 (IP2C)-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kgABA ~10 mg/kg, Maintenance Period (MP)Placebo, MPABA ~10 mg/kg, Open-Label Period (OL)
Started141139701405150000
Completed106104531201921000
Not completed353517203229000
Withdrew: Death100000000
Withdrew: Adverse event342410000
Withdrew: Lack of efficacy26248877000
Withdrew: Lost to follow-up222301000
Withdrew: Withdrawal by subject353520000
Withdrew: Subject no longer meets study criteria001000000
Withdrew: Administrative reason by sponsor00002221000
Withdrew: Other001000000
Maintenance Period (MP)
Participant flow — Maintenance Period (MP)
MilestoneInduction Period Cohort 1 (IP1C)-Abatacept (ABA) 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-PlaceboIP Cohort 2 (IP2C)-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kgABA ~10 mg/kg, Maintenance Period (MP)Placebo, MPABA ~10 mg/kg, Open-Label Period (OL)
Started00000065660
Completed00000015110
Not completed00000050550
Withdrew: Death000000100
Withdrew: Adverse event000000130
Withdrew: Lack of efficacy00000025240
Withdrew: Lost to follow-up000000120
Withdrew: Withdrawal by subject000000110
Withdrew: Administrative reason by sponsor00000021250
Open-Label Period (OL)
Participant flow — Open-Label Period (OL)
MilestoneInduction Period Cohort 1 (IP1C)-Abatacept (ABA) 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-PlaceboIP Cohort 2 (IP2C)-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kgABA ~10 mg/kg, Maintenance Period (MP)Placebo, MPABA ~10 mg/kg, Open-Label Period (OL)
Started00000000349
Completed000000000
Not completed00000000349
Withdrew: Death000000001
Withdrew: Adverse event0000000010
Withdrew: Lack of efficacy00000000161
Withdrew: Lost to follow-up000000004
Withdrew: Withdrawal by subject0000000020
Withdrew: Pregnancy000000001
Withdrew: Administrative reason by sponsor00000000145
Withdrew: Other000000007

Outcome measures

PrimaryInduction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.

Time frame:
Week 12 (Day IP-85)
Reported as:
Number · participants
Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)
participantsInduction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-Placebo
Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)30261441
Statistical analysis
  • Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg vs IP1C-Placebo · Cochran-Mantel-Haenszel · p = 0.124 (Cochran-Mantel-Haenszel Chi square p-value and RR along with 95% confidence interval provided, adjusting for randomization strata (whether a participant had an inadequate response and/or intolerance to anti-TNF therapy).) · Risk ratio (rr): 0.73 · 95% CI 0.48 to 1.09Conditional on ABA 30/\~10 mg/kg vs PLA comparison being statistically significant at 5% level, ABA \~10 vs PLA to be tested at 5% significance level.
SecondaryIP; Baseline Mayo Score: IP1C

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.

Time frame:
Baseline
Reported as:
Mean · units on a scale
IP; Baseline Mayo Score: IP1C
units on a scaleIP1C-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kg,IP1C-Placebo
IP; Baseline Mayo Score: IP1C8.9 ± 1.748.8 ± 1.738.6 ± 1.828.8 ± 1.59
SecondaryIP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

Time frame:
Week 12 (Day IP-85)
Reported as:
Number · participants
IP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C
participantsInduction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-Placebo
IP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C36415
Statistical analysis
  • Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg vs IP1C-Placebo · Cochran-Mantel-Haenszel · Risk ratio (rr): 0.2 · 95% CI .06 to 0.67Conditional on both the remission comparison for ABA 30/\~10 vs PLA, and the clinical response comparison for ABA\~10 vs PLA being significant at 5%, the secondary remission comparison for ABA \~10 vs PLA will be tested at 5%.
SecondaryIP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point

Time frame:
Week 12 (Day IP-85)
Reported as:
Number · participants
IP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C
participantsInduction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-Placebo
IP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C24201136
Statistical analysis
  • Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg vs IP1C-Placebo · Cochran-Mantel-Haenszel · Risk ratio (rr): 0.66 · 95% CI 0.42 to 1.05Conditional on both the comparison for mucosal healing for ABA 30/\~10 vs PLA and the comparison for remission for ABA \~10 vs. PLA being significant, the comparison for mucosal healing for ABA \~10 vs PLA will be tested at 5%.
SecondaryIP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.

Time frame:
Week 12 (Day IP-85)
Reported as:
Number · participants
IP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C
participantsIP1C-PlaceboIP1C-ABA 3 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 30/~10 mg/kg
IP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C41142630
Statistical analysis
  • IP1C-Placebo vs IP1C-ABA 3 mg/kg vs IP1C-ABA ~10 mg/kg vs IP1C-ABA 30/~10 mg/kg · Cochran-Armitage Trend Test · p = 0.044 (All statistical testing was performed at a pre-specified alpha-level of 5%.)
SecondaryIP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C

The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.

Time frame:
Baseline
Reported as:
Mean · units on a scale
IP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C
units on a scaleIP1C-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kg,IP1C-Placebo
IP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C120.0 ± 35.43121.5 ± 36.42126.9 ± 35.93124.3 ± 33.43
SecondaryIP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C

The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.

Time frame:
Baseline (Day IP-1), Day IP-85 (Week 12)
Reported as:
Mean · units on a scale
IP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C
units on a scaleInduction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-Placebo
IP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C9.45 ± 3.51413.36 ± 3.4769.87 ± 5.10823.68 ± 3.268
SecondaryIP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.

Time frame:
Day IP-85 (Week 12)
Reported as:
Number · participants
IP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C
participantsInduction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-Placebo
Rectal Subscore=028361647
Rectal Subscore=131301327
SecondaryIP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.

Time frame:
Day IP-85 (Week 12)
Reported as:
Number · participants
IP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C
participantsInduction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-Placebo
Stool Frequency Subscore=0138414
Stool Frequency Subscore=114211032
SecondaryIP; Number of Participants With Mayo Physician Global Assessment (PGA) Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.

Time frame:
Day IP-85 (Week 12)
Reported as:
Number · participants
IP; Number of Participants With Mayo Physician Global Assessment (PGA) Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C
participantsInduction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-Placebo
PGA Subscore=024311
PGA Subscore=122251534
SecondaryIP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C

The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

Time frame:
Week 12 (Day IP-85)
Reported as:
Number · participants
IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C
participantsIP1C-PlaceboIP1C-ABA 3 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 30/~10 mg/kg
IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C12478
Statistical analysis
  • IP1C-Placebo vs IP1C-ABA 3 mg/kg vs IP1C-ABA ~10 mg/kg vs IP1C-ABA 30/~10 mg/kg · Cochran-Armitage Trend Test · p = 0.149 (All statistical testing was performed at a pre-specified alpha-level of 5%)
SecondaryIP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C

The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

Time frame:
Week 12 (Day IP-85)
Reported as:
Number · participants
IP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C
participantsInduction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-Placebo
IP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C87412
PrimaryMaintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 12

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.

Time frame:
Month 12 (Day MP-365)
Reported as:
Number · participants
Maintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 12
participantsABA ~10 mg/kg, MPPlacebo, MP
Maintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 121111
SecondaryIP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C

The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

Time frame:
Week 12 (Day IP-85)
Reported as:
Number · participants
IP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C
participantsInduction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-Placebo
IP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C2004
PrimaryOpen-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
Day OL-1 through the end of the OL
Reported as:
Number · participants
Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation
participantsABA ~10 mg/kg, OL
AEs241
Related AEs100
Deaths1
SAEs66
Related SAEs9
AEs Leading to Discontinuation7
SAEs Leading to Discontinuation4
PrimaryOL; Number of Participants With AEs of Special Interest

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

Time frame:
Day OL-1 through Day OL-729
Reported as:
Number · participants
OL; Number of Participants With AEs of Special Interest
participantsABA ~10 mg/kg, OL
Infections and Infestations127
Serious Infections9
Opportunistic Infections-Total2
Opportunistic Infections-cytomegalovirus1
Opportunistic Infections-listeriosis1
Malignancies-Total5
Malignancies-Basal Cell Carcinoma2
Malignancies-Bowen's Disease1
Malignancies-Chronic Myeloid Leukemia1
Malignancies-Squamous Cell Carcinoma1
Autoimmune Disorders-Total5
Autoimmune Disorders-episcleritis2
Autoimmune Disorders-scleritis1
Autoimmune Disorders-anemia hemolytic autoimmune1
Autoimmune Disorders-psoriasis1
Acute Infusional AEs12
Peri-infusional AEs25
SecondaryIP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

Time frame:
Week 12 (Day IP-85)
Reported as:
Number · participants
IP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C
participantsInduction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-Placebo
IP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C44113
SecondaryIP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation: IP1C + IP2C

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
Day IP-1 through Day IP-85
Reported as:
Number · participants
IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation: IP1C + IP2C
participantsIP1C-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kg,IP1C-PlaceboIP Cohort 2 (IP2C)-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kg
AEs859239862627
Related AEs484623371011
Deaths100000
SAEs22208764
Related SAEs411310
AEs Leading to Discontinuation462510
SAEs Leading to Discontinuation121310
SecondaryIP; Number of Participants With AEs Of Special Interest: IP1C + IP2C

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

Time frame:
Day IP-1 through Day IP-85
Reported as:
Number · participants
IP; Number of Participants With AEs Of Special Interest: IP1C + IP2C
participantsIP1C-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kg,IP1C-PlaceboIP Cohort 2 (IP2C)-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kg
Infections and Infestations2329825127
Serious Infections501000
Opportunistic Infections-Total011000
Opportunistic Infections-candidiasis001000
Opportunistic Infections-esophageal candidiasis010000
Malignancies-Total100100
Malignancies-basal cell carcinoma100000
Malignancies-malignant melanoma000100
Autoimmune Disorders-Total210400
Autoimmune Disorders-uveitis110100
Autoimmune Disorders-episcleritis000100
Autoimmune Disorders-scleritis000100
Autoimmune Disorders-rheumatoid arthritis000100
Autoimmune Disorders-psoriasis100000
Acute Infusional AEs440200
Peri Infusional AEs172051424
SecondaryIP; Number of Participants With Physical Examination Findings: IP1C + IP2C

Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).

Time frame:
Day IP-1 through Day IP-85

No measurements were reported for this outcome.

SecondaryIP; Number of Participants With Marked Hematology Laboratory Abnormalities: IP1C

High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL.

Time frame:
Day IP-1 through Day IP-85
Reported as:
Number · participants
IP; Number of Participants With Marked Hematology Laboratory Abnormalities: IP1C
participantsIP1C-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kg,IP1C-Placebo
Low HGB; n=136, n=134, n=67, n=1333261
Low hematocrit; n=134, n=133, n=67, n=1311241
Low erythrocytes; n=136, n=134, n=67, n=1332241
Low PLT; n=136, n=133, n=66, n=1331010
High PLT; n=136, n=133, n=66, n=1330200
Low leukocytes; n=136, n=134, n=67, n=1331041
High leukocytes; n=136, n=134, n=67, n=13310635
Low neutrophils + bands; n=136, n=134, n=67, n=1310010
High eosinophils; n=136, n=134, n=67, n=1316434
High monocytes; n=136, n=134, n=67, n=1310010
Low lymphocytes; n=136, n=134, n=67, n=13123131126
SecondaryIP; Number of Participants With Marked Liver and Kidney Function and Electrolyte Laboratory Abnormalities: IP1C

Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): \>2 x ULN; aspartate aminotransferase (AST): \>3 x ULN; alanine aminotransferase (ALT): \>3 x ULN; G-Glutamyl transferase (GGT): \>2 x ULN; Bilirubin: \>2 x ULN; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; Sodium (Na): \<0.95 x LLN/ \>1.05 x ULN; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; calcium (Ca): \<0.8 x LLN/\>1.2 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN

Time frame:
Day IP-1 through Day IP-85
Reported as:
Number · participants
IP; Number of Participants With Marked Liver and Kidney Function and Electrolyte Laboratory Abnormalities: IP1C
participantsIP1C-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kg,IP1C-Placebo
High ALP, n=137, n=135, n=66, n=1351000
High ALT; n=137, n=135, n=66, n=1350100
High GGT; n=137, n=135, n=66, n=1356202
High BUN; n=127, n=130, n=62, n=1240223
High creatinine; n=137, n=135, n=66, n=1350001
Low Na; n=138, n=135, n=66, n=1350020
Low K; n=138, n=135, n=66, n=1351220
High K; n=138, n=135, n=66, n=1350101
Low Ca; n=137, n=135, n=66, n=1350120
Low P; n=137, 135, n=66, n=1350103
SecondaryIP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP1C

Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3

Time frame:
Day IP-1 through Day IP-85
Reported as:
Number · participants
IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP1C
participantsIP1C-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kg,IP1C-Placebo
Low Glu; n=88, n=91, n=41, n=1051620
High Glu; n=88, n=91, n=41, n=1050010
Low protein; n=137, n=135, n=66, n=1355330
High protein; n=137, n=135, n=66, n=1350100
Low albumin; n=137, n=135, n=66, n=1357530
High urine protein; n=132, n=129, n=66, n=1285324
High urine Glu; n=132, n=129, n=66, n=1284124
High urine blood; n=132, n=129, n=66, n=12867411
High leukocyte esterase; n=54, n=51, n=27, n=521522
High urine RBC; n=47, n=42, n=17, n=5298412
High urine WBC; n=64, n=56, n=27, n=581421314
SecondaryIP; Number of Participants With Marked Hematology, Liver and Kidney Function, and Electrolyte Laboratory Abnormalities: IP2C

High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; Sodium (Na): \<0.95 x LLN/ \>1.05 x ULN; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN;

Time frame:
Day IP-1 through Day IP-85
Reported as:
Number · participants
IP; Number of Participants With Marked Hematology, Liver and Kidney Function, and Electrolyte Laboratory Abnormalities: IP2C
participantsIP2C-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kg
Low HGB; n=50, n=4922
Low hematocrit; n=50, n=4910
Low erythrocytes; n=50, n=4910
High PLT; n=50, n=4901
Low leukocytes; n=50, n=4901
High leukocytes; n=50, n=4934
High eosinophils; n=49, n=4931
High monocytes; n=49, n=4901
Low lymphocytes; n=49, n=4953
High BUN; n=46, n=4431
High creatinine; n=50, n=5010
Low Na; n=50, n=5010
Low K; n=50, n=5021
Low P; n=50, n=5010
Low Glu; n=37, n=2802
High Glu; n=37, n=2802
Low protein; n=50, n=5020
Low albumin; n=50, n=5020
High urine protein; n=50, n=4804
High urine Glu; n=50, n=4802
High urine blood; n=50, n=4823
High leukocyte esterase; n=21, n=1642
High urine RBC; n=15, n=2004
High urine WBC; n=24, n=2376
SecondaryIP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP2C

Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3

Time frame:
Day IP-1 through Day IP-85
Reported as:
Number · participants
IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP2C
participantsIP2C-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kg
Low Glu; n=37, n=2802
High Glu; n=37, n=2802
Low protein; n=50, n=5020
Low albumin; n=50, n=5020
High urine protein; n=50, n=4804
High urine Glu; n=50, n=4802
High urine blood; n=50, n=4823
High leukocyte esterase; n=21, n=1642
High urine RBC; n=15, n=2004
High urine WBC; n=24, n=2376
SecondaryIP; Number of Participants With Abatacept-Induced Antibodies: IP1C + IP2C

A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

Time frame:
For participants treated in MP: Day IP-1 (Baseline) to Day MP-1 (Day IP-85). For participants treated in OL directly after IP: Day IP-1 to Day OL-1. For participants treated only in IP: All measurements after Day IP-1 (including follow-up visits)
Reported as:
Number · participants
IP; Number of Participants With Abatacept-Induced Antibodies: IP1C + IP2C
participantsIP1C+IP2C: ABA 30/~10 mg/kgIP1C+IP2C: ABA ~10 mg/kgIP1C-ABA 3 mg/kg
Total6194
CTLA4/Possibly Ig2174
Ig and/or Ig Junction430
SecondaryMP; Number of Participants in Clinical Remission at Month 12

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

Time frame:
Month 12 (Day MP-365)
Reported as:
Number · participants
MP; Number of Participants in Clinical Remission at Month 12
participantsABA ~10 mg/kg, MPPlacebo, MP
MP; Number of Participants in Clinical Remission at Month 1289
SecondaryMP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) at Month 12

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point

Time frame:
Month 12 (Day MP-365)
Reported as:
Number · participants
MP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) at Month 12
participantsABA ~10 mg/kg, MPPlacebo, MP
MP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) at Month 121110
SecondaryMP; Number of Participants in Clinical Remission at Both Month 6 and Month 12

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

Time frame:
Month 6 (Day MP-169), Month 12 (Day MP-365)

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids and Achieved Clinical Remission by Month 12

Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

Time frame:
Day MP-365 (Month 12)

No measurements were reported for this outcome.

SecondaryMP; Mean Change From Baseline to Month 12 in IBDQ

The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.

Time frame:
Day MP-365

No measurements were reported for this outcome.

SecondaryMP; Mean Change From Baseline to Month 12 in Short Form-36 (SF-36)

The SF-36 is a validated instrument to measure health-related quality of life across multiple disease states. Individual subscale scores and 2 summary scores are calculated: (1) physical component summary (PCS) which includes physical functioning, role-physical, bodily pain, and general health; (2) mental component summary (MCS) which includes vitality, social functioning, role-emotional, and mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight, with values ranging from worse health (0) to best health (100).

Time frame:
Day MP-365

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids for 90 Consecutive Days and Achieved Clinical Remission by Month 12

Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

Time frame:
Day MP-365 (Month 12)

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Month 12

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.

Time frame:
Day MP-365 (Month 12)

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Month 12

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.

Time frame:
Day MP-365 (Month 12)

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With Mayo PGA Subscores Indicating Mild Disease (≤1 Point) at Month 12

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.

Time frame:
Day MP-365 (Month 12)

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With Clinical Response at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)

The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

Time frame:
Month 12 (Day MP-365)

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With Clinical Remission at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)

The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

Time frame:
Month 12 (Day MP-365)

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With Clinical Mucosal Healing at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.

Time frame:
Month 12 (Day MP-365)

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With Abatacept-Induced Antibodies

A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

Time frame:
For participants not entering OL: All measurements starting after Day MP-1 (including follow-up visits). For participants entering OL: From first measurement after Day MP-1 to Day MP-365 (Day OL-1).
Reported as:
Number · participants
MP; Number of Participants With Abatacept-Induced Antibodies
participantsABA ~10 mg/kg, MPPlacebo, MP
Total820
CTLA4/Possibly Ig817
Ig and/or Ig Junction03
SecondaryMP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
Day MP-1 through Day MP-365
Reported as:
Number · participants
MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation
participantsABA ~10 mg/kg, MPPlacebo, MP
AEs3936
Related AEs1213
Deaths10
SAEs74
Related SAEs22
AEs Leading to Discontinuation13
SAEs Leading to Discontinuation11
SecondaryMP; Number of Participants With AEs of Special Interest

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

Time frame:
Day MP-1 through Day MP-365
Reported as:
Number · participants
MP; Number of Participants With AEs of Special Interest
participantsABA ~10 mg/kg, MPPlacebo, MP
Infections and Infestations3936
Serious Infections52
Opportunistic Infections-Total10
Opportunistic Infections-pneumonia herpes viral10
Malignancies-Total01
Malignancies-breast cancer01
Autoimmune Disorders-Total20
Autoimmune Disorders-erythema nodosum10
Autoimmune Disorders-pemphigoid10
Acute Infusional AEs21
Peri-infusional AEs32
SecondaryMP; Number of Participants With Physical Examination Findings

Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).

Time frame:
Day IP-85 through Day MP-365

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With Marked Hematology Laboratory Abnormalities

High=greater than ULN, Low=lower than LLN. LLN/ULN= HGB: \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; PLT: \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL; GGT: \>2 x ULN; Bilirubin: \>2 x ULN; BUN: \>2 x BL; Na: \<0.95 x LLN/ \>1.05 x ULN; K: \<0.9 x LLN/ \>1.1 x ULN; Ca: \<0.8 x LLN/\>1.2 x ULN

Time frame:
Day IP-85 through Day MP-365
Reported as:
Number · participants
MP; Number of Participants With Marked Hematology Laboratory Abnormalities
participantsABA 30/~10 mg/kg, MPABA ~10 mg/kg, MP
Low HGB; n=64, n=6112
Low hematocrit; n=64, n=6032
Low erythrocytes; n=64, n=6112
High PLT; n= 64, n=6101
Low leukocytes; n=64, n=6020
High leukocytes; n=64, n=6020
Low neutrophils + bands; n=64, n=6010
High eosinophils; n=64, n=6023
High monocytes; n=64, n=6010
Low lymphocytes; n=64, n=6076
High lymphocytes; n=64, n=6010
High GGT; n=64, n=6232
High bilirubin, n=64, n=6110
High BUN; n=57, n=5943
Low Na; n=64, n=6201
Low K; n=64, n=6211
Low Ca; n=64, n=6110
Low Glu; n=45, n=3802
High Glu; n=45, n=3833
Low protein; n=64, n=6101
High urine protein; n=58, n=5841
High urine Glu; n=58, n=5821
High urine blood; n=58, n=5837
High leukocyte esterase; n=23, n=1825
High urine RBC; n=24, n=1744
High urine WBC; n=29, n=21810
SecondaryMP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities

Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; fasting serum Glu: \<0.8 x LLN/ \>1.5 x ULN; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3

Time frame:
Day IP-85 through Day MP-365
Reported as:
Number · participants
MP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities
participantsABA 30/~10 mg/kg, MPABA ~10 mg/kg, MP
Low Glu; n=45, n=3802
High Glu; n=45, n=3833
Low protein; n=64, n=6101
High urine protein; n=58, n=5841
High urine Glu; n=58, n=5821
High urine blood; n=58, n=5837
High leukocyte esterase; n=23, n=1825
High urine RBC; n=24, n=1744
High urine WBC; n=29, n=21810
PrimaryOL; Number of Participants With Physical Examination Findings

Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).

Time frame:
Day OL-1 through Day OL-729

No measurements were reported for this outcome.

SecondaryOL; Number of Participants With Clinical Response Over Time

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.

Time frame:
Day OL-1 through Day OL-729
Reported as:
Number · participants
OL; Number of Participants With Clinical Response Over Time
participantsABA ~10 mg/kg, OL
Day OL-365 (n=163)44
Day OL-729 (n=4)0
SecondaryOL; Number of Participants With Clinical Remission Over Time

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.

Time frame:
Day OL-1 through Day OL-729
Reported as:
Number · participants
OL; Number of Participants With Clinical Remission Over Time
participantsABA ~10 mg/kg, OL
Day OL-365 (n=163)18
Day OL-729 (n=4)0
PrimaryOL; Number of Participants With Marked Hematology Laboratory Abnormalities

High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL.

Time frame:
Day OL-1 through Day OL-729
Reported as:
Number · participants
OL; Number of Participants With Marked Hematology Laboratory Abnormalities
participantsABA ~10 mg/kg, OL
Low HGB; n=32620
Low hematocrit; n=32217
Low erythrocytes; n=3266
High PLT; n=3233
Low leukocytes; n=3263
High leukocytes; n=32618
Low neutrophils + bands; n=3241
High eosinophils; n=32417
High monocytes; n=3242
Low lymphocytes; n=32443
PrimaryOL; Number of Participants With Liver and Kidney Function and Electrolyte Laboratory Abnormalities

Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): \>2 x ULN; aspartate aminotransferase (AST): \>3 x ULN; alanine aminotransferase (ALT): \>3 x ULN; G-Glutamyl transferase (GGT): \>2 x ULN; Bilirubin: \>2 x ULN; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; calcium (Ca): \<0.8 x LLN/\>1.2 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN

Time frame:
Day OL-1 through Day OL-729
Reported as:
Number · participants
OL; Number of Participants With Liver and Kidney Function and Electrolyte Laboratory Abnormalities
participantsABA ~10 mg/kg, OL
High ALP, n=3314
High AST, n=3313
High ALT; n=3313
High GGT; n=33217
High bilirubin, n=3311
High BUN; n=31010
High creatinine; n=3305
Low K; n=3317
Low Ca; n=3302
Low P; n=3304
High P, n=3301
PrimaryOL; Number of Participants With Chemistry and Urinalysis Laboratory Abnormalities

Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; fasting serum Glu: \<0.8 x LLN/ \>1.5 x ULN; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3

Time frame:
Day OL-1 through Day OL-729
Reported as:
Number · participants
OL; Number of Participants With Chemistry and Urinalysis Laboratory Abnormalities
participantsABA ~10 mg/kg, OL
Low Glu; n=2454
High Glu; n=2456
Low protein; n=3313
Low albumin; n=33112
High urine protein; n=31211
High urine Glu; n=3124
High urine blood; n=31227
High leukocyte esterase; n=12210
High urine RBC; n=11522
High urine WBC; n=15045
SecondaryOL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) During OL

The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point

Time frame:
Open-Label Period (Day OL-1 through Day OL-729)
Reported as:
Number · participants
OL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) During OL
participantsABA ~10 mg/kg, MPPlacebo, MP
OL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) During OL00
SecondaryOL; Number of Participants With Clinical Response or Clinical Remission Upon Retreatment With Abatacept Among Those Who Received Abatacept in the IP or MP Period

The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Clinical remission = Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Change from Baseline= post-Baseline - Baseline value.

Time frame:
Last Study Visit (Day OL-729)

No measurements were reported for this outcome.

SecondaryOL; Number of Participants With Abatacept-Induced Antibodies

A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

Time frame:
For participants receiving OL medication, all measurements starting after Day OL-1 (including follow-up visits and at 56 and 85 days after last dose)
Reported as:
Number · participants
OL; Number of Participants With Abatacept-Induced Antibodies
participantsABA ~10 mg/kg, OL
Total66
CTLA4/Possibly Ig59
Ig and/or Ig Junction11
SecondaryOL; Number of Participants Using Corticosteroids During OL

Participants taking oral corticosteroids (equivalent of ≤ 30 mg prednisone daily) must have met minimum treatment duration at entry into IP and had stable dose for ≥2 weeks prior to entry into the IP.

Time frame:
Day OL-1 through Day OL-729

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABA 30/~10 mg/kg,IP1C—22/141 (15.6%)49/141 (34.8%)
ABA 30/~10mg/kg,IP2C—6/51 (11.8%)13/51 (25.5%)
ABA 3 mg/kg,IP1C—8/70 (11.4%)21/70 (30%)
ABA ~10 mg/kg,IP1C—20/139 (14.4%)48/139 (34.5%)
ABA ~10mg/kg,IP2C—4/50 (8%)13/50 (26%)
ABA ~10mg/kg, MP—7/65 (10.8%)20/65 (30.8%)
ABA ~10 mg/kg, OL—66/349 (18.9%)137/349 (39.3%)
Placebo, IP1C—7/140 (5%)45/140 (32.1%)
Placebo, MP—4/66 (6.1%)24/66 (36.4%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventABA 30/~10 mg/kg,IP1CABA 30/~10mg/kg,IP2CABA 3 mg/kg,IP1CABA ~10 mg/kg,IP1CABA ~10mg/kg,IP2CABA ~10mg/kg, MPABA ~10 mg/kg, OLPlacebo, IP1CPlacebo, MP
COLITIS ULCERATIVEGastrointestinal disorders13/1415/515/7014/1394/503/6542/3494/1401/66
ABDOMINAL PAINGastrointestinal disorders0/1411/510/700/1390/500/650/3490/1400/66
ABDOMINAL PAIN UPPERGastrointestinal disorders0/1411/510/700/1390/500/650/3490/1400/66
ANAEMIABlood and lymphatic system disorders2/1411/510/701/1390/500/652/3490/1400/66
SEPSISInfections and infestations0/1410/510/700/1390/501/651/3490/1400/66
PNEUMONIAInfections and infestations1/1410/510/700/1390/501/651/3490/1400/66
VARICELLAInfections and infestations0/1410/510/700/1390/501/650/3490/1400/66
ANAL ABSCESSInfections and infestations0/1410/510/700/1390/501/650/3490/1400/66
APPENDICITISInfections and infestations0/1410/510/700/1390/501/650/3490/1400/66
CLOSTRIDIAL INFECTIONInfections and infestations0/1410/510/700/1390/501/650/3490/1400/66
Most frequent other events
Showing 10 of 14
Most frequent other events
EventABA 30/~10 mg/kg,IP1CABA 30/~10mg/kg,IP2CABA 3 mg/kg,IP1CABA ~10 mg/kg,IP1CABA ~10mg/kg,IP2CABA ~10mg/kg, MPABA ~10 mg/kg, OLPlacebo, IP1CPlacebo, MP
HEADACHENervous system disorders17/1413/517/7012/1396/503/6524/34912/1405/66
PYREXIAGeneral disorders9/1413/516/706/1391/502/6517/3492/1401/66
NASOPHARYNGITISInfections and infestations5/1412/512/703/1391/503/6529/3498/1403/66
NAUSEAGastrointestinal disorders8/1411/513/7011/1393/502/6518/3499/1404/66
BACK PAINMusculoskeletal and connective tissue disorders3/1411/510/702/1390/504/6513/3493/1405/66
ARTHRALGIAMusculoskeletal and connective tissue disorders4/1411/512/706/1390/502/6518/3494/1405/66
COUGHRespiratory, thoracic and mediastinal disorders6/1411/512/704/1391/504/6513/3493/1405/66
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/1411/511/702/1390/502/6522/3495/1402/66
INFLUENZAInfections and infestations1/1411/510/703/1390/504/6512/3493/1401/66
ABDOMINAL PAINGastrointestinal disorders8/1412/511/701/1393/503/6516/3495/1404/66

Baseline characteristics

Age, Customized
Age, Customized(participants)Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-PlaceboIP Cohort 2 (IP2C)-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kgTotal
<30 years26231834124117
30-50 years708435733032324
>50 years45321733914150
Sex: Female, Male
Sex: Female, Male(Participants)Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-PlaceboIP Cohort 2 (IP2C)-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kgTotal
Female575226662126248
Male848744743024343
Region of Enrollment
Region of Enrollment(participants)Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-PlaceboIP Cohort 2 (IP2C)-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kgTotal
United States434222552013195
Ireland1001013
Italy76232121
Switzerland1112106
United Kingdom0003249
India121210105251
France712661537
Czech Republic0100001
Mexico20141087968
Puerto Rico0101002
Canada9122131340
Brazil1055114641
Poland2201106
Belgium46150117
Australia874131134
South Africa98532027
Germany2201229
Netherlands25122113
Korea, Republic of43120111
Participants with Inadequate Response/Intolerance to Prior Anti-Tumor (TNF) Therapy (Infliximab)
Participants with Inadequate Response/Intolerance to Prior Anti-Tumor (TNF) Therapy (Infliximab)(participants)Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kgIP1C-ABA ~10 mg/kgIP1C-ABA 3 mg/kgIP1C-PlaceboIP Cohort 2 (IP2C)-ABA 30/~10 mg/kgIP2C-ABA ~10 mg/kgTotal
Inadequate Response/Intolerant to prior Infliximab454624452121202
No Inadequate Response/Intolerance to Infliximab969346953029389
08

Study locations

144 sites
  • University Of Alabama At Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • The Permanente Medical Group, Inc
    Sacramento, California 95825, United States
  • Western States Clinical Research Inc.
    Wheatridge, Colorado 80033, United States
  • Litchfield County Gastroenterology Assoc.
    Torrington, Connecticut 06790, United States
  • University Of Florida
    Gainesville, Florida 32610, United States
  • Borland-Groover Clinic
    Jacksonville, Florida 32256, United States
  • Miami Research Associates
    Miami, Florida 33143, United States
  • Shafran Gasteroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University Of Chicago Hospitals
    Chicago, Illinois 60637, United States
  • Health Science Center
    Pratt, Kansas 67124, United States
  • University Of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
  • University Of Louisville
    Louisville, Kentucky 40202, United States
  • Gulf Coast Research
    Lafayette, Louisiana 70503, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • Minnesota Gastroenterology, P.A.
    Plymouth, Minnesota 55446, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Kansas City Gastroenterology And Hepatology
    Kansas City, Missouri 64131, United States
  • Center For Digestive & Liver Diseases, Inc.
    Mexico, Missouri 65265, United States
  • Aga Clinical Research Associates, Llc
    Egg Harbor Twp, New Jersey 08234, United States
  • Hudson Valley Medical Research Llc
    Fishkill, New York 12524, United States
  • Long Island Clinical Research
    Great Neck, New York 11021, United States
  • Mount Sinai School Of Medicine
    New York, New York 10029, United States
  • University Of Rochester Medical Center
    Rochester, New York 14642, United States
  • Good, Larry I.
    Rockville Centre, New York 11570, United States
  • Gastrointestinal Resrch Assoc.
    Setauket, New York 11733, United States
  • University Of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Charlotte Gastroenterology & Hepatology, Pllc
    Charlotte, North Carolina 28207, United States
  • Hanover Medical Specialists, P.A.
    Wilmington, North Carolina 28401, United States
  • Piedmont Medical Research Associates
    Winston Salem, North Carolina 27103, United States
  • Gastroenterology Specialists, Inc.
    Canton, Ohio 44718, United States
  • Consultants For Clinical Research, Inc.
    Cincinnati, Ohio 45219, United States
  • Gastrointestinal & Liver Diseases Consultants
    Dayton, Ohio 45415, United States
  • Oklahoma Foundation For Digestive Research
    Oklahoma City, Oklahoma 73104, United States
  • Options Health Research, Llc
    Tulsa, Oklahoma 74104, United States
  • Healthcare Research Consultants
    Tulsa, Oklahoma 74135, United States
  • Hospital Of The University Of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny Center For Digestive Health
    Pittsburgh, Pennsylvania 15212, United States
  • Medical University Of South Carolina
    Charleston, South Carolina 29425, United States
  • Gastroenterology Center Of The Midsouth, P.C.
    Germantown, Tennessee 38138, United States
  • Memphis Gastroenterology Group
    Germantown, Tennessee 38138, United States
  • Nashville Medical Research
    Nashville, Tennessee 37205, United States
  • Austin Gastroenterology, Pa
    Austin, Texas 78705, United States
  • Alamo Medical Research
    San Antonio, Texas 78215, United States
  • Gastroenterology Clinic Of San Antonio
    San Antonio, Texas 78229, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Tacoma Digestive Disease Research Ctr.
    Tacoma, Washington 98405, United States
  • Local Institution
    Garran, Australian Capital Territory 2605, Australia
  • Local Institution
    Camperdown, New South Wales 2050, Australia
  • Local Institution
    Herston, Queensland 4029, Australia
  • Local Institution
    South Brisbane, Queensland 4101, Australia
  • Local Institution
    Bedford Park, South Australia 5042, Australia
  • Local Institution
    Launceston, Tasmania 7250, Australia
  • Local Institution
    Box Hill, Victoria 3128, Australia
  • Local Institution
    Fitzroy, Victoria 3065 VIC, Australia
  • Local Institution
    South Ballarat, Victoria 3350, Australia
  • Local Institution
    Fremantle, Western Australia 6160, Australia
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Salvador, Bahia 42700, Brazil
  • Local Institution
    Goiania, Goias 74535, Brazil
  • Local Institution
    Curitiba, Parana 80060, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 90035, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 90610, Brazil
  • Local Institution
    Campinas, Sao Paulo 13070, Brazil
  • Local Institution
    Santo Andre - Sp, Sao Paulo 09060, Brazil
  • Local Institution
    Santos, Sao Paulo 11075, Brazil
  • Local Institution
    Rio De Janeiro, 21941, Brazil
  • Local Institution
    Sao Paulo, 01246, Brazil
  • Local Institution
    Vancouver, British Columbia V5Z 1H2, Canada
  • Local Institution
    Vancouver, British Columbia V6Z 2K5, Canada
  • Local Institution
    Kingston, Ontario K7L 5G2, Canada
  • Local Institution
    London, Ontario N6A 5A5, Canada
  • Local Institution
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution
    Toronto, Ontario M3N 2V7, Canada
  • Local Institution
    Toronto, Ontario M5G 1X5, Canada
  • Local Institution
    Levis, Quebec G6V 3Z1, Canada
  • Local Institution
    Montreal, Quebec H1T 2M4, Canada
  • Local Institution
    Quebec, G1L 3L5, Canada
  • Local Institution
    Brno - Bohunice, 625 00, Czech Republic
  • Local Institution
    Ceske Budejovice, 370 87, Czech Republic
  • Local Institution
    Amiens Cedex 1, 80054, France
  • Local Institution
    Clichy, 92110, France
  • Local Institution
    Lille Cedex, 59037, France
  • Local Institution
    Nice, 06200, France
  • Local Institution
    Paris, 75475, France
  • Local Institution
    Pessac, 33604, France
  • Local Institution
    Toulouse, 31059, France
  • Local Institution
    Kiel, 24105, Germany
  • Local Institution
    Muenster, 48129, Germany
  • Local Institution
    Muenster, 48159, Germany
  • Local Institution
    Hyderabad, Andhra Pradesh 500082, India
  • Local Institution
    Kochi, Kerala 682304, India
  • Local Institution
    Mumbai, Maharashtra 400020, India
  • Local Institution
    Bangalore, 560017, India
  • Local Institution
    Bangalore, 560034, India
  • Local Institution
    Delhi, 110076, India

Showing the first 100 of 144 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul;143(1):62-69.e4. doi: 10.1053/j.gastro.2012.04.010. Epub 2012 Apr 12. PubMed 22504093 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jun 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2006
First posted
Dec 12, 2006
Start
Dec 2006
Primary completionActual
Jun 2009
CompletionActual
Nov 2009
Results first posted
Dec 2, 2010
Last update
Mar 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00410410
Responsible party
Sponsor
First posted
Dec 12, 2006
Start date
Dec 2006
Primary completion
Jun 2009
Completion
Nov 2009
Results posted
Dec 2, 2010
Last update
Mar 24, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion